---
title: "bet_inhibitor"
date: "2024-08-24"
tags:
  - building
---

> [!NOTE]
> ðŸŒ± created from: [[treatment-of-myelofibrosis]]

# bet_inhibitor

- Design: Phase I dose-escalation/expansion study, multicenter, open-label
- Number of patients: Not specified
- Patients characteristics: Patients with relapsed or refractory advanced myelofibrosis or other advanced hematologic malignancies
- Agent: BET inhibitor INCB057643 as monotherapy or in combination with JAK inhibitor ruxolitinib
- Treatment line: Relapsed or refractory patients, some in combination therapy
- Trial Acronym/NCTId Number: Not specified
- Comparison of efficacy:

| Parameter           | Result       |
| ------------------- | ------------ |
| Symptom improvement | Effective    |
| Treatment of anemia | Some success |
| Side effects        | Minimal      |

- Highlight of toxicity: Dosing at a level that did not produce side effects seen with other BET inhibitors
- One-line summary: INCB057643, a novel BET inhibitor, shows promise as a targeted therapy for advanced myelofibrosis and other hematologic malignancies, with minimal side effects and potential for improved outcomes.
